Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20858617 | 1.00 | NOS3 (0.43) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL22889 | 1.00 | NOS3 (0.43) | NOS3NOS1POLBGAANPC1 | |
| Ammonia Solution, Strong SCHEMBL28456086 | 0.98 | NOS3 (0.42) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL6335314 | 0.98 | NOS3 (0.45) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL10427141 | 0.93 | NOS3 (0.42) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL868782 | 0.93 | NOS3 (0.42) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL5832697 | 0.93 | NOS3 (0.47) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL8031217 | 0.93 | NOS3 (0.42) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL867932 | 0.93 | NOS3 (0.42) | NOS3NOS1POLBGAANPC1 | |
| SCHEMBL1954285 | 0.93 | NOS3 (0.42) | NOS3NOS1POLBGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | MYH2, MYO3B, MYO1B | NOS3 2126/4885NOS1 1325/4885POLB 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.